Edited by Ma JY
Published online Dec 15, 2000. doi: 10.3748/wjg.v6.i6.783
Revised: July 19, 2000
Accepted: September 12, 2000
Published online: December 15, 2000
- Citation: Huang XQ. Helicobacter pylori infection and gastrointestinal hormones: A review. World J Gastroenterol 2000; 6(6): 783-788
- URL: https://www.wjgnet.com/1007-9327/full/v6/i6/783.htm
- DOI: https://dx.doi.org/10.3748/wjg.v6.i6.783
Helicobacter pylori (Hp) infection is closely related to gastrointestinal hormones and involves the formation of gastritis, gastric carcinoma and peptic ulcer[1-7]. Its pathogenesis relevant to pathophysiological changes of gastrointestinal hormones are described as follows according to individual hormone.
Gastrin is a basic stimulus to parietal cells in producing gastric acid, and shows two ways in acid production: one directly stimulates parietal cell and the other acts on enterochromaffin-like (ECL) cell to release histamine by which stimulates parietal cells. So the formation of gastric acid and hyperchlorhydria is one of the physiopathological implications of gastrin. Hp infection in patients leading to increased release of gastrin from antral G cells and hypergastrinemia formation is currently an interesting medical problem[8-11].
It is well known that Hp infection induces hypergastrinemia. In patients with normal gastroscopic features, those infected with Hp had significantly higher basal serum gastrin levels than non-infected individuals, and were similar to DU patients who are almost entirely infected with Hp. Therefore, hypergastrinemia seems to be associated with Hp infection, and is not a distinctive feature of DU disease.
Hp-infected hypergastrinemia may be produced by cytokines[13,14]: ① TNF-α: antral G cells (both human and canine) undergoing TNF-α-pretreatment significantly increased in both basal and bombesin-stimulated gastrin release (compared to control); TNF-α increased in Hp infection, so the Hp-infected hypergastrinemia may be due to TNF-α-stimulation to G cells; ② IL-8: IL-8 stimulated gastrin release from isolated G cells, and this effect was dose de pendent and potentiated by Hp extract products.
The density of antral G cells was evaluated by expression of gastrin mRNA. The G cell density in patients with Hp infection was significantly higher than in controls; after eradication of Hp, the density was significantly lower as compared with pre-eradication value. The study suggests that increased gastrin mRNA is directly related to Hp infection.
In a study of DU and non-ulcer dyspepsia (NUD), the Hp (absence of CagA gene and presence of VacA alleles s2 and m2) was only found in NUD (not with DU), and associated with lesser extent of gastrin increase and higher value of tryptase. The CagA negative s2 m2 strain of Hp may be less dangerous for the gastric mucosa than other Hp strains, since it enhances tryptase production by gastric mucosal mast cells. This enzyme is thought to stimulate tissue turnover and favour wound healing. We may predict that the development of DU or NUD would probably depend upon the strains of Hp.
Combined serum levels of gastrin and pepsinogen (PG) were used to study Hp infection[17-19]. As a screening procedure to show the status of Hp infection, both levels significantly increased in Hp infection, and significantly decreased after Hp eradication. The high levels may indicate Hp infection and the significant decrease after treatment may indicate cure, and reappearance of high levels suggests reinfection. The level of PG-IIcould be more useful in this situation. To classify DU, serum PG-I concentrations reflect the chief cell mass. Blood samples were taken before and at 15, 30, and 60 min after test meal, and the serum concentrations of fasting PG-Iand gastrin were measured after meal. The area, under the serum gastrin 3 h curve, was taken as integrated gastrin response (IGR). The DU patients (Hp positive) were divided into two groups (hyper-IGR and normal-IGR, with significant difference). The hyper-IGR DU patients had higher serum PG-I concentrations, and suggest to be acid hypersecretors.
Change of acid (parietal cells) sensitivity to gastrin. In a study of three groups of subjects (DU patients, Hp-negative and Hp-positive healthy volunteers), the MAO (maximal acid output), and the acid sensitivity to gastrin were measured (serum gastrin required to achieve 50% MAO during intravenous administration of gastrin). The result revealed that the Hp positive healthy volunteers showed significantly higher gastrin concentrations, which meant less sensitive than the other two groups. The DU group had significantly higher MAO. Conclusively, a combination of decreased sensitivity to gastrin in infected healthy volunteers and increased maximal acid secretory capacity in patients with DU underlies their different acid response to Hp-induced hypergastrinemia, and they are caused by the hypergastrinemia.
In patients with end stage of renal disease on dialysis, the hypergastrinemia was induced by Hp infection in stomach, and the serum gastrin concentrations were decreased to normal range following eradication of Hp. Either Hp infection or omeprazole administration can cause hypergastrinemia, and both of them would cause severe hypergastrinemia, which may exert potential deleterious effects. Since omeprazole treatment produced a similar percentage increase in serum gastrin, it is appropriate to eradicate Hp prior to commencing proton pump inhibitor treatment in order to reduce the degree of hypergast-rinemia[21,22].
Evidence indicated that gastrin concentrations decreased to normal range after Hp eradication[11,23-26].
Hp infection is associated with exaggeration of gastrin release following meals or bombesin stimulation attributed to a defect of SS secretion of antral D cells[27,28]. Mucosal cytokines (TNF-α and IL-8 are predominant ones) were increased in Hp infection. TNF-α- could stimulate the isolated canine gastric D cells to increase SS release dose-dependently, and the stimulatory effect was potentiated by IL-8 and inhibited by octreotide. In conclusions, TNF-α can regulate SS release from cultured D cells in a divergent manner.
In Hp infection, SS contents in antral mucosa and gastric juice, and number of D cells were decreased, and less expressions of SS mRNA and Hp eradication resulted in restoration of those indices, suggesting the Hp inhibition on SS release. In different SS concentrations in vitro, SS at 10-11 mol·L-1 significantly suppressed the proliferation of cultured Hp. SS at a similar level in human gastric juice (≈ 10-11mol·L-1) indicated an inhibitory effect of SS in the gastric lumen on Hp proliferation in humans.
LPS inhibits the binding of SS to its gastric mucosal receptors. The antiulcer agents, sucralfate, ebrotidine and sulglycotide, possess the ability to restore the receptor-SS binding by 92.5%, 94.9% and 84%, respectively. Conclusively, LPS of Hp inhibits the SS binding to its receptor, and results in less SS effect, more gastrin and gastric acid secretion, and ulcer formation[31,32].
SS from D cells inhibits G cells, and decreased SS results in increase in gastrin secretion; gastrin stimulates, and SS inhibits parietal cells in gastric acid release. So, gastrin and SS form the gastrin-SS equilibrium, which was even called mechanism of gastric regulatory physiology. Phenomena related to imbalance of gastrin-SS equilibrium are as follows: ① hypergastrinemia: Hp infection influences D cells firstly to diminish SS release, then increases release of gastrin and acid, leading to the milieu favoring ulcer formation; eradication of Hp gets rid of the imbalance; the large mass of parietal cells in DU patients might be due to the long-term trophic effect of gastrin on parietal cells, and 6-12 mo after Hp eradication, the MAO (representingparietal cell mass) fell significantly; this investigation supports the viewpoint; ② atrophic pangastritis: the degree and extent of gastritis affect destructive number of cells (D, G and parietal) which lead to the released amounts of SS, gastrin and acid in severe destruction; the resultant hyperchlorhydria tends to ulcer formation, and hypochlorhydria to develop carcinoma; pangastritis involving much more D cells and parietal cells may play an important role in imbalance of gastrin-SS equilibrium;③ increased cytokines (TNF-α and IL-1β) in Hp infection lead to gastrin-SS imbalance with hyperchlorhydria or hypochlorhydria, and then forming DU or carcinoma; ④ hypergastrinemia of Hp (CagA) gastritis is due to decreased density of D cells; ⑤ water extract of either Hp (CagA and VacA) positive or Hp (CagA and VacA) negative delayed ulcer healing as compared with saline controls in rats, because of impairment of gastrin-SS link; ⑥ in Hp (+) DU patients, the amount change of T lymphocyte subsets was obviously correlated with those of gastric active inflammation, serum gastrin, and SS in gastric juice, indicating that gastrin and SS played a role in immune regulation. Gastrin-SS equilibrium restores after Hp eradication. SS may be the most widely effective gastrointestinal hormone in human body, and it is worthy of further studies.
GRP can stimulate gastric acid secretion, and is particularly valuable in detecting disturbances of gastric secretory function of patients with DU and Hp infection. Its attractiveness lies in the fact that it simultaneously activates many physiological control processes, both stimulatory and inhibitory. This facilitates the detection of a defect in any of the controls involved in regulating biological function. Other gastrointestinal functions such as gallbladder contraction, pancreatic secretion and gastroesophageal motility are subject to complex regulatory controls, and GRP may also be of value in investigating disturbances of these processes.
GRP stimulates gastrin secretion, but also inhibits its release via SS. Exogenous GRP stimulates a greater increase in plasma gastrin concentrations in Hp infected patients than in uninfected controls. This is due to less inhibition on gastrin mRNA in Hp infection, probably because of low stimulated SS levels in Hp infection.
In a study of gastric acid increment in DU patients, the GRP stimulated PAO (PAOGRP) and pentagastrin stimulated PAO (PAOPG) were measured in Hp positive DU patients and in Hp negative as controls. This study has shown that BAO, PAOGRP and PAOPG are significantly higher in Hp positive DU than in Hp negative controls. All decreased significantly six months after Hp eradication to fall within the range of controls. These results are compatible with a hypothesis that acid hypersecretion in DU is caused by Hp infection. Peterson’s investigation showed a similar result that GRP stimulated hypergastrinemia and hyperchlorhydria which were lowered to normal range after Hp eradication.
EGF was found in at least seven individuals, and four of them were expressed in gastrointestinal tract. They were EGF, transforming growth factor alpha (TGF-α), amphiregulin (AR), and heparin binding-epidermal growth factor (HB-EGF). EGF and TGFα have the same receptor, EGFr. EGFs combined to their receptors which widely existed over cellular membrane to regulate cell growth and play biological roles. EGF serves gastrointestinal tract with cell growth, ulcer healing and suppression of acid secretion.
Acute exposure to Hp caused cell damage and impaired the processes of cell migration and proliferation in cultured gastric mucosal cells in vitro. EGF-related growth factors play a major role in protecting gastric mucosa against injury, and are involved in the process of gastric mucosal healing. In the study of Romano et al, using MKN 28 gastric mucosal cells (derived from gastric adenocarcinoma), Hp increased mucosal (MKN 28 cells) generation of EGF-related peptides; the inhibitory effect of Hp on the reparative events mediated by EGF-related growth factors might play a role in the pathogenesis of Hp-induced gastrointestinal injury.
Hp inhibits both EGF binding to its receptors and EGF-stimulated gastric cell proliferation, and they are the mechanisms of peptic ulcer formation and its difficulty in healing[49-52]. In a study of gastric luminal release of EGF, the stomach was capable of secreting large amounts of EGF, and pentagastrin appeared to be a potent stimulus to gastric EGF release; the Hp infection reduced the release of gastric EGF, and eradication of Hp resulted in the augmentation of basal and pentagastrin-induced EGF release into the stomach. Since the eradication of Hp infection in DU patients resulted in DU healing which was accompanied by an increase in EGF release, conclusively, EGF plays a crucial role in DU healing[53,54]. Accordingly, it also plays a major role in ulcer formation.
The overexpression of C-myc gene protein and EGFr (receptor of EGF) may be the molecular basis for hyperproliferation of gastric mucosal epithelium in Hp infection.
The EGF concentrations in gastric juice were affected by Hp and pH. There were four situations in NUD patients studied: ① EGF was 80% lower in Hp (+) than in Hp (-); ② those with pH < 4.0 in gastric juice had significantly lower EGF concentrations; ③ those with gastric juice pH > 4 showed similar concentrations of EGF in both Hp (+) and Hp (-) groups; ④ those with both Hp (+) and pH < 4.0 had further reduction in EGF concentrations. These results suggested that Hp may elaborate factors that accelerate its proteolytic degradation or inhibit its rate of synthesis and/or secretion; pH reduction (< 4) may increase EGF degradation; the diminished content of EGF at low pH, especially in Hp-positive patients, may facilitate the development of mucosal damage. The TGF-α-concentrations in gastric juice remained unaffected by Hp or pH.
In studying Hp protease activity and its suppression by sulglycotide, it was found that the Hp protease evoked a 61.7% degradation of PDGF (platelet derived growth factor) and a 62.3% degradation of TGFβ; introduction of sulglycotide to the reaction assay system caused a dose-dependent inhibition in PDGF and TGFβ- proteolysis by the Hp protease; the maximal inhibitory effect was obtained with sulglycotide at 100 mg·L-1, at which dose an 84.4% decrease in PDGF and 88.3% decrease in TGFβ-degradation were achieved; the results provide a strong evidence for the effectiveness of sulglicotide in the protection of gastric mucosal growth factors against degradation by Hp.
EGF and TGF-α- are potent gastric secretory inhibitors, mitogens, and mucosal protectors, and their gastric mucosal expression and luminal contents are closely related to Hp infection. A study of DU and NUD patients showed that chronic Hp infection and resulting antral gastritis were associated with increased plasma gastrin and increased mucosal cell proliferation, probably due to enhanced expression of EGF and TGF-α; the Hp eradication decreased plasma gastrin, but the increase in gastric EGF and TGF-α contents was sustained, suggesting that they may be involved in ulcer healing.
Effect of Hp infection on gastric mucosal expression of EGF, TGF-α, and EGFr. In a study of Konturek et al, the DU patients with Hp (+) were accompanied by increased mucosal expression and contents of TGF-α, EGF, and EGFr, and eradication of Hp infection enhanced all of them and contributed to ulcer healing. Russo et al also indicated that Hp eradication resulted in a significant increase in expression of EGF and TGF-α; Hp possibly inhibited the mucosal expression of EGF and TGF-α. The results from different authors seem not wholly consistent. It is appropriate to study further.
It has been revealed that patients with DU and gastric carcinoma possessed 3 common features which contributed to the pathogenesis of the two diseases: they were Hp infection, increase in gastric mucosal and luminal growth factors (EGF, TGF-α), and hypergastrinemia. They remained different in hyperchlorhydria in DU patients, and in patients with gastric carcinoma. These changes returned to normal values two years after Hp eradication in DU patients. The hypochlorhydria was possibly due to atrophy of oxyntic mucosa and overexpression of growth factors in gastric mucosa may be implicated in the pathogenesis of both DU and gastric cancer. Hypergastrinemia, hypochlorhydria, and increase in mucosal growth factors are predisposing to gastric cancer.
Taha et al measured gastric and fasting serum concentrations of IGF-Iin patients with and without Hp infection. As a result, IGF-I was detected at very low concentrations in gastric juice and in mucosal incubates. The median serum IGF-Iconcentration was 88 μg·L-1 in the patients infected with Hp compared with 90 μg·L -1 in the non-infected controls; IGF-Iconcentrations significantly dropped to 77 μg·L-1 following eradication therapy. Conclusively, the similarity in baseline ICF-Iconcentrations in the presence and absence of Hp suggests that their subsequent drop after treatment is more likely to be produced by the treatment.
It is true that Hp gastritis resulted in increased secretion of basal and meal-stimulated gastrin, which is also a physiologic amplifier of insulin release. In order to confirm whether Hp gastritis may enhance nutrient-stimulated insulin secretion, both glucose and a mixed meal stimulated insulin response were investigated in Hp positive gastritis and Hp negative control subjects. The areas under the curve (AUC) for serum insulin following both oral glucose and a mixed meal in the patients with Hp gastritis were significantly higher than those of non Hp controls. After Hp eradication, the AUC for serum insulin following oral glucose and mixed meal decreased significantly, and serum basal and meal-stimulated gastrin levels also obviously decreased. These results suggest that Hp gastritis enhances glucose and meal-stimulated insulin release probably by increasing gastrin secretion.
Glicentin seems to promote intestinal metaplasia (IM) in the gastric mucosa. In order to clarify whether Hp infection accelerates glicentin gene expression, glicentin mRNA was investigated using gastric biopsies. The results disclosed that glicentin mRNA was significantly correlated with histological IM and was positively correlated with Hp infection. Conclusion is that Hp infection is associated with the induction of glicentin in the gastric mucosa, thus supporting the hypothesis that Hp infection accelerates IM of the stomach.
In healthy subjects, CCK has the feedback control of postprandial gastrin release and gastric acid secretion, but in Hp-positive DU patients the CCK loses its control effect. Eradication of Hp restores the inhibitory effect of CC K on postprandial gastrin release and gastric acid secretion. This suggests that Hp infection eliminates or lessens the inhibitory effect of CCK on gastrin release.
There was no significant difference of serum GIP levels among groups of gastrectomy (total, subtotal), healthy subjects, Hp infection, age, gender, body mass index, smoking. Only the elapsed time since operation in patients following total gastrectomy exhibited a significant positive correlation with their GIP levels (r = 0.89, P < 0.05). Hence GIP is less important in mediating gastric acid secretion, and Hp does not influence its levels.
|1.||Du SJ, Liu ZC. Helicobacter pylori infection and stomach disease. Xin Xiaohuabingxue Zazhi. 1996;4:161. [Cited in This Article: ]|
|2.||Qia XP, Wang ZQ, Xu Z, Hu YQ. The association of Helicobacter pylori with chronic gastritis. Xin Xiaohuabingxue Zazhi. 1996;4:593-594. [Cited in This Article: ]|
|3.||Gao XH, Pan BR. Helicobacter pylori infection and gastric cancer. Xin Xiaohuabingxue Zazhi. 1995;3:223-224. [Cited in This Article: ]|
|4.||Zhuang XQ, Lin SR. Research of Helicobacter pylori infection in precancerous gastric lesions. World J Gastroenterol. 2000;6:428-429. [PubMed] [Cited in This Article: ]|
|5.||Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujian Province, China. World J Gastroenterol. 2000;6:374-376. [PubMed] [Cited in This Article: ]|
|6.||Li ZX, Zhang WD, Zhou DY, Zhang YL, Guo XP, Yang HT. Relationship between Helicobacter pylori and duodenal ulcer. Xin Xiaohuabingxue Zazhi. 1996;4:153-155. [Cited in This Article: ]|
|7.||Zhao H, Zhang ZS. The relationship between Helicobacter pylori and chronic gastritis, gastric ulcer. Xin Xiaohuabingxue Zazhi. 1996;4:165. [Cited in This Article: ]|
|8.||Gillen D, el-Omar EM, Wirz AA, Ardill JE, McColl KE. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology. 1998;114:50-57. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 3.0] [Reference Citation Analysis (0)]|
|9.||Hurlimann S, Dür S, Schwab P, Varga L, Mazzucchelli L, Brand R, Halter F. Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and meal-stimulated plasma gastrin release in the absence of peptic ulcer disease. Am J Gastroenterol. 1998;93:1277-1285. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis (0)]|
|10.||Annibale B, Rindi G, D'Ambra G, Marignani M, Solcia E, Bordi C, Delle Fave G. Antral gastrin cell hyperfunction and Helicobacter pylori infection. Aliment Pharmacol Ther. 1996;10:607-615. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis (0)]|
|11.||Maconi G, Lazzaroni M, Sangaletti O, Bargiggia S, Vago L, Bianchi Porro G. Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol. 1997;92:1844-1848. [PubMed] [Cited in This Article: ]|
|12.||Gisbert JP, Boixeda D, Vila T, Cantón R, Alvarez Baleriola I, Defarges V, Martín de Argila C. [Helicobacter pylori infection and basal levels of serum gastrins in patients with duodenal ulcer and subjects with normal endoscopy]. Med Clin (. Barc). 1996;106:325-328. [PubMed] [Cited in This Article: ]|
|13.||Beales IL, Post L, Calam J, Yamada T, Delvalle J. Tumour necrosis factor alpha stimulates gastrin release from canine and human antral G cells: possible mechanism of the Helicobacter pylori-gastrin link. Eur J Clin Invest. 1996;26:609-611. [PubMed] [Cited in This Article: ]|
|14.||Beales I, Blaser MJ, Srinivasan S, Calam J, Pérez-Pérez GI, Yamada T, Scheiman J, Post L, Del Valle J. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology. 1997;113:465-471. [PubMed] [Cited in This Article: ]|
|15.||Gupta A, Rana SV, Goenka MK, Kukreja RS. Transcriptional expression of gastrin mRNA in Helicobacter pylori infected patients. Indian J Med Res. 1997;105:136-140. [PubMed] [Cited in This Article: ]|
|16.||Basso D, Navaglia F, Brigato L, Di Mario F, Rugge M, Plebani M. Helicobacter pylori non-cytotoxic genotype enhances mucosal gastrin and mast cell tryptase. J Clin Pathol. 1999;52:210-214. [PubMed] [Cited in This Article: ]|
|17.||Vaira D, Holton J, Menegatti M, Landi F, Ricci C, Ali A, Gatta L, Farinelli S, Acciardi C, Massardi B. Blood tests in the management of Helicobacter pylori infection. Italian Helicobacter pylori Study Group. Gut. 1998;43 Suppl 1:S39-S46. [PubMed] [Cited in This Article: ]|
|18.||Gisbert JP, Boixeda D, Al-Mostafa A, Vila T, de Rafael L, Alvarez Baleriola I, de Argila CM, Abraira V. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Eur J Gastroenterol Hepatol. 1999;11:189-200. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis (0)]|
|19.||Kamada T, Haruma K, Komoto K, Mihara M, Sumii K, Kajiyama G. Comparison of meal-stimulated serum gastrin response in Helicobacter pylori-positive duodenal ulcer and asymptomatic volunteers with and without H. pylori infection. Helicobacter. 1999;4:170-177. [PubMed] [Cited in This Article: ]|
|20.||Tokushima H, Tamura H, Murakawa M, Matsumura O, Itakura Y, Itoyama S, Mitarai T, Isoda K. Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease. Intern Med. 1998;37:435-439. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis (0)]|
|21.||Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena E, Nelis GF, Festen HP, Jansen EH, Biemond I, Lamers CB, Meuwissen SG. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther. 1998;12:605-612. [PubMed] [Cited in This Article: ]|
|22.||el-Nujumi A, Williams C, Ardill JE, Oien K, McColl KE. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut. 1998;42:159-165. [PubMed] [Cited in This Article: ]|
|23.||Ohkusa T, Takashimizu I, Fujiki K, Araki A, Honda K, Shimoi K, Sakurazawa T, Horiuchi T, Suzuki S, Ariake K. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol. 1997;25:317-322. [PubMed] [Cited in This Article: ]|
|24.||Jurgos L, Duris I, Bátovský M, Simkovicová M, Pauer M, Dorociak F, Majercík M, Kratochvílová H, Valko L, Paulen P. [Triple combination antimicrobial therapy of Helicobacter pylori and basal levels of serum gastrin]. Bratisl Lek Listy. 1996;97:131-133. [PubMed] [Cited in This Article: ]|
|25.||Verhulst ML, Hopman WP, Tangerman A, Jansen JB. Eradication of Helicobacter pylori infection in patients with non-ulcer dyspepsia. Effects on basal and bombesin-stimulated serum gastrin and gastric acid secretion. Scand J Gastroenterol. 1995;30:968-973. [PubMed] [Cited in This Article: ]|
|26.||Gisbert JP, Boixeda D, Vila T, de Rafael L, Redondo C, de Argila CM. Basal and stimulated gastrin levels and gastric acid output five months after therapy for Helicobacter pylori eradication in duodenal ulcer patients. J Clin Gastroenterol. 1996;22:90-95. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis (0)]|
|27.||Chamouard P, Walter P, Wittersheim C, Demuynck P, Meunier O, Baumann R. Antral and fundic D-cell numbers in Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1997;9:361-365. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis (0)]|
|28.||Yu JY, Wang JL, Yao L, Zheng JY, Hu M. The changes of antral endocrine cells in Helicobacter pylori infection. China Natl J New Gastroenterol. 1995;1:25-26. [Cited in This Article: ]|
|29.||Beales I, Calam J, Post L, Srinivasan S, Yamada T, DelValle J. Effect of transforming growth factor alpha and interleukin 8 on somatostatin release from canine fundic D cells. Gastroenterology. 1997;112:136-143. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 1.4] [Reference Citation Analysis (0)]|
|30.||Yamashita K, Kaneko H, Yamamoto S, Konagaya T, Kusugami K, Mitsuma T. Inhibitory effect of somatostatin on Helicobacter pylori proliferation in vitro. Gastroenterology. 1998;115:1123-1130. [PubMed] [Cited in This Article: ]|
|31.||Piotrowski J, Slomiany A, Slomiany BL. Helicobacter pylori lipopolysaccharide inhibition of gastric somatostatin receptor: effect of sucralfate. Biochem Mol Biol Int. 1997;42:545-551. [PubMed] [Cited in This Article: ]|
|32.||Piotrowski J, Skrodzka D, Slomiany A, Slomiany BL. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide. Gen Pharmacol. 1997;28:705-708. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis (0)]|
|33.||Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med. 1995;27:569-573. [PubMed] [Cited in This Article: ]|
|34.||Calam J. Helicobacter pylori and hormones. Yale J Biol Med. 1996;69:39-49. [PubMed] [Cited in This Article: ]|
|35.||Götz JM, Veenendaal RA, Biemond I, Muller ES, Veselic M, Lamers CB. Serum gastrin and mucosal somatostatin in Helicobacter pylori-associated gastritis. Scand J Gastroenterol. 1995;30:1064-1068. [PubMed] [Cited in This Article: ]|
|36.||Calam J. Helicobacter pylori and somatostatin cells. Eur J Gastroenterol Hepatol. 1998;10:281-283. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis (0)]|
|37.||Tham TC, Chen L, Dennison N, Johnston CF, Collins JS, Ardill JE, Buchanan KD. Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans. Eur J Gastroenterol Hepatol. 1998;10:289-291. [PubMed] [Cited in This Article: ]|
|38.||Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage Its effect on acid and gastrin physiology. Gastroenterology. 1997;113:S43-S9; discussion S50. [PubMed] [Cited in This Article: ]|
|39.||Kim JH, Park HJ, Cho JS, Lee KS, Lee SI, Park IS, Kim CK. Relationship of CagA to serum gastrin concentrations and antral G, D cell densities in Helicobacter pylori infection. Yonsei Med J. 1999;40:301-306. [PubMed] [Cited in This Article: ]|
|40.||Brzozowski T, Konturek PC, Konturek SJ, Kwiecien S, Pajdo R, Karczewska E, Stachura J, Hahn EG. Water extracts of Helicobacter pylori delay healing of chronic gastric ulcers in rats: role of cytokines and gastrin-somatostatin link. Digestion. 1999;60:22-33. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis (0)]|
|41.||Nie ZH, Zhu Y, Zhang M, Feng FB, Chen Y, Wang BZ, Geng YL, Chen XZ. Relationship of T lymphocyte subsets in peripheral blood with gastric mucosal active inflammation, Gas and SS contents in patients with duodenal ulcer. Shijie Huaren Xiaohua Zazhi. 1999;7:338-340. [Cited in This Article: ]|
|42.||Huang XQ. Somatostatin-Probably the most widely effective gastrointestinal hormone in human body. China Natl J New Gastroenterol. 1997;3:201-204. [Cited in This Article: ]|
|43.||McColl KE, el-Omar E. Review article: gastrin releasing peptide and its value in assessing gastric secretory function. Aliment Pharmacol Ther. 1995;9:341-347. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis (0)]|
|44.||Gibbons AH, Legon S, Walker MM, Ghatei M, Calam J. The effect of gastrin-releasing peptide on gastrin and somatostatin messenger RNAs in humans infected with Helicobacter pylori. Gastroenterology. 1997;112:1940-1947. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 0.7] [Reference Citation Analysis (0)]|
|45.||Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut. 1996;38:663-667. [PubMed] [Cited in This Article: ]|
|46.||Peterson WL. Gastrin and acid in relation to Helicobacter pylori. Aliment Pharmacol Ther. 1996;10 Suppl 1:97-102. [PubMed] [Cited in This Article: ]|
|47.||Chen YF, Yamada T (ed). Textbook of gastrointestinal pepiide hormones, basic and clinical aspects. Beijing: Peking Union Medical College and Beijing Medical University Joint Press 1997; 304-316. [Cited in This Article: ]|
|48.||Romano M, Ricci V, Di Popolo A, Sommi P, Del Vecchio Blanco C, Bruni CB, Ventura U, Cover TL, Blaser MJ, Coffey RJ. Helicobacter pylori upregulates expression of epidermal growth factor-related peptides, but inhibits their proliferative effect in MKN 28 gastric mucosal cells. J Clin Invest. 1998;101:1604-1613. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 2.7] [Reference Citation Analysis (0)]|
|49.||Tunio AM, Holton J, Hobsley M. Gastric juice epidermal growth factor concentration and Helicobacter pylori in patients with duodenal ulcer. Br J Surg. 1995;82:1204-1206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis (0)]|
|50.||Fujiwara Y, Wyle F, Arakawa T, Domek MJ, Fukuda T, Kobayashi K, Tarnawski A. Helicobacter pylori culture supernatant inhibits binding and proliferative response of human gastric cells to epidermal growth factor: implications for H. pylori interference with ulcer healing. Digestion. 1997;58:299-303. [PubMed] [Cited in This Article: ]|
|51.||Pai R, Wyle FA, Cover TL, Itani RM, Domek MJ, Tarnawski AS. Helicobacter pylori culture supernatant interferes with epidermal growth factor-activated signal transduction in human gastric KATO III cells. Am J Pathol. 1998;152:1617-1624. [PubMed] [Cited in This Article: ]|
|52.||Seto K, Hayashi-Kuwabara Y, Yoneta T, Suda H, Tamaki H. Vacuolation induced by cytotoxin from Helicobacter pylori is mediated by the EGF receptor in HeLa cells. FEBS Lett. 1998;431:347-350. [PubMed] [Cited in This Article: ]|
|53.||Konturek PC, Ernst H, Konturek J, Bobrzyński A, Kwiecień N, Faller G, Gedliczka O, Hahn EG. Salivary and gastric luminal release of epidermal growth factor under basal conditions and after pentagastrin stimulation in healthy subjects and in duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol. 1996;47:187-194. [PubMed] [Cited in This Article: ]|
|54.||Chen XQ, Zhang WD, Jiang B, Song YG, Reng RZ, Zhou DY. Reduced secretion of epidermal growth factor in duodenalulcer patients with Helicobacter pylori infection. China Natl J New Gastroenterol. 1997;3:31-34. [Cited in This Article: ]|
|55.||Gao JH, Liang HJ, Liu WW, Fang DC, Wang ZH. Expression of C-myc gene protein and epidermal growth factor receptorin gastric mucosa pre and post-Helicobacter pylori clearance. Shijie Huaren Xiaohua Zazhi. 1999;7:1018-1019. [Cited in This Article: ]|
|56.||Marcinkiewicz M, Van Der Linden B, Peura DA, Goldin G, Parolisi S, Sarosiek J. Impact of Helicobacter pylori colonization on immunoreactive epidermal growth factor and transforming growth factor-alpha in gastric juice. Its potential pathogenetic implications. Dig Dis Sci. 1996;41:2150-2155. [PubMed] [Cited in This Article: ]|
|57.||Piotrowski J, Slomiany A, Slomiany BL. Suppression of Helicobacter pylori protease activity towards growth factors by sulglycotide. J Physiol Pharmacol. 1997;48:345-351. [PubMed] [Cited in This Article: ]|
|58.||Konturek PC, Bobrzynski A, Konturek SJ, Bielanski W, Faller G, Kirchner T, Hahn EG. Epidermal growth factor and transforming growth factor alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication. Scand J Gastroenterol. 1998;33:143-151. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis (0)]|
|59.||Konturek PC, Ernst H, Konturek SJ, Bobrzyński AJ, Faller G, Klingler C, Hahn EG. Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. Gut. 1997;40:463-469. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis (0)]|
|60.||Russo F, Messa C, Amati L, Caradonna L, Leoci C, Di Matteo G, Jirillo E, Di Leo A. The influence of Helicobacter pylori eradication on the gastric mucosal content of epidermal growth factor, transforming growth factor-alpha, and their common receptor. Scand J Gastroenterol. 1998;33:271-275. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis (0)]|
|61.||Konturek PC, Bielański W, Bobrzyński A, Hahn EG, Konturek SJ. Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol. 1997;48:375-382. [PubMed] [Cited in This Article: ]|
|62.||Taha AS, Beastall G, Morton R, Park RH, Beattie AD. Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy. J Clin Pathol. 1996;49:676-678. [PubMed] [Cited in This Article: ]|
|63.||Açbay O, Celik AF, Gündoğdu S. Does Helicobacter pylori-induced gastritis enhance food-stimulated insulin release. Dig Dis Sci. 1996;41:1327-1331. [PubMed] [Cited in This Article: ]|
|64.||Ishihara S, Fukuda R, Moriyama N, Ishimura N, Kaji T, Kushiyama Y, Amano K, Hirakawa K, Amano Y, Adachi K. Helicobacter pylori infection accelerates gene expression of glicentin in the gastric mucosa. Its association with intestinal metaplasia of the stomach. Scand J Gastroenterol. 1997;32:460-464. [PubMed] [Cited in This Article: ]|
|65.||Konturek JW, Gillessen A, Konturek SJ, Domschke W. Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients. Gut. 1995;37:482-487. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis (0)]|
|66.||Wang YY, Lee CT, Lu CL, Chen CY, Chang FY, Lee SD, Doong ML, Wang PS. Gastric inhibitory polypeptide appears less important in mediating acid secretion. Hepatogastroenterology. 1999;46:2105-2109. [PubMed] [Cited in This Article: ]|